The market for asthma drugs is heavily saturated with existing products, making the bar high for the safety and efficacy of new treatments. But there is still an unmet need among patients who do not respond to existing therapy, including inhaled corticosteroids. In recent years, drug makers have turned their attention to developing drugs for this severe patient sub-group.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?